Home > Press release: New open-access book provides guidance ...

Data from the largest US Lyme disease registry suggests that 90% of PLD patients are excluded from clinical trials.

Bio-Path Holdings, Inc. (NASDAQ:BPTH) recently announced significant developments in its scientific rationale for the development of BP1001-A to address obesity in patients with Type 2 diabetes.

But the most likely rationale is a possible perjury charge ... Office of Science and Technology Policy], the National ...

In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic ...

Chemical analysis revealed a mixture of psychotropic plants, alcohol and bodily fluids in the mug, which is thought to be ...

Pancreatic cancer has a poor prognosis accounting for a 5-year overall survival rate lower than 10%. This proportion could reach about one-third of patients ...

Patients with myelofibrosis who cleared driver mutations within 30 days after hematopoietic stem cell transplantation ...

A recent study published in Synthese challenges the default collection and reliance on ethno-racial data in biomedical ...

But crime and terrorism risk are bad rationales for immigration restrictions ... nations – make disproportionate contributions to scientific innovation, and are also disproportionately likely ...

Its proposal, which is currently being prepared along with the rationale, is scheduled to ... which weakened their scientific credibility." To address this, the commission collaborated with ...